The CT and dominant models of the VEGF +936C>T polymorphism were associated with decreased CAD susceptibility in CAD patients with MetS (CC vs. CT, AOR = 0.643, 95% CI = 0.417–0.991, p = 0.045; CC vs. CT + TT AOR = 0.633, 95% CI = 0.415–0.965, p = 0.034). This evidence concerns the gene VEGFA and metabolic syndrome.